US 10,376,481 B2
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Noah Bell, Berkeley, CA (US); Christopher Carreras, Belmont, CA (US); Michael Robert Leadbetter, San Leandro, CA (US); Jason Gustaf Lewis, Castro Valley, CA (US); Jeffrey W. Jacobs, San Mateo, CA (US); Irina Dotsenko, San Jose, CA (US); Dean Dragoli, Los Altos, CA (US); Ying He, Pleasanton, CA (US); Andrew King, Dublin, CA (US); and Matthew Siegel, Menlo Park, CA (US)
Assigned to ARDELYX, INC., Fremont, CA (US)
Filed by ARDELYX, INC, Fremont, CA (US)
Filed on Jan. 9, 2017, as Appl. No. 15/402,213.
Application 15/402,213 is a continuation in part of application No. 14/421,451, abandoned, previously published as PCT/GB2013/052192, filed on Aug. 20, 2013.
Claims priority of provisional application 61/691,635, filed on Aug. 21, 2012.
Prior Publication US 2017/0368004 A1, Dec. 28, 2017
Int. Cl. A61K 31/17 (2006.01); A61K 31/4545 (2006.01); A61K 31/25 (2006.01); A61K 31/18 (2006.01); A61K 31/167 (2006.01); A61K 31/03 (2006.01); A61K 31/10 (2006.01); A61K 31/015 (2006.01); A61K 31/40 (2006.01); A61K 31/4453 (2006.01)
CPC A61K 31/17 (2013.01) [A61K 31/03 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 31/25 (2013.01); A61K 31/40 (2013.01); A61K 31/4453 (2013.01); A61K 31/4545 (2013.01); A61K 31/015 (2013.01); A61K 31/10 (2013.01)] 32 Claims
 
1. A method for inhibiting sodium absorption in the gastrointestinal tract of a mammal comprising administering to said mammal a pharmaceutically effective amount of a compound having the following structure:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof.